Reuptake Inhibitors

Reuptake inhibitors are a class of drugs commonly used in the treatment of neurological disorders such as depression, anxiety, and attention deficit hyperactivity disorder (ADHD). These drugs work by inhibiting the reuptake of neurotransmitters, which are chemicals responsible for transmitting signals from one nerve cell to another in the brain. By inhibiting the reuptake of neurotransmitters, reuptake inhibitors allow these chemicals to remain in the nerve synapse for longer periods of time, thereby increasing the transmission of the signal between the neurons. This increased transmission can lead to positive changes in mood, behavior, and cognition for individuals with neurological disorders. Selective serotonin reuptake inhibitors (SSRIs) are the most common type of reuptake inhibitors used in the treatment of depression and anxiety. These drugs specifically target the reuptake of serotonin, a neurotransmitter that plays a crucial role in regulating mood, anxiety, and sleep. By increasing the availability of serotonin in the brain, SSRIs can improve symptoms of depression and anxiety. Other types of reuptake inhibitors include norepinephrine and dopamine reuptake inhibitors. These drugs are commonly used in the treatment of ADHD, as they increase the availability of these neurotransmitters in the brain, which can improve attention, focus, and impulse control. While reuptake inhibitors have been shown to be effective in treating neurological disorders, they can also have side effects, such as nausea, insomnia, and sexual dysfunction. Therefore, it is important for individuals considering reuptake inhibitors as a treatment option to discuss the benefits and risks with their healthcare provider before starting any medication.


From: Neurobiology

Related Article For "Reuptake Inhibitors"

About (2) results

Article:

Nucleoside and Nucleotide Reverse Transcriptase Inhibitors Induce Aging by Inhibiting Telomerase Function

Journal:

Clinical Research In HIV AIDS And Prevention

Article:

Cross-Reactivity between COX-2 Inhibitors in Patients with Cross-Reactive Hypersensitivity to NSAIDs

Journal:

Public Health International